Vimarsana
Biggest News Aggregation in the World

Page 8 - Presentation Details News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presentation Details. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presentation Details Today - Breaking & Trending Today

Editas Medicine to Present Clinical Data from the RUBY and - Vimarsana News

Editas Medicine to Present Clinical Data from the RUBY and

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children’s to...

BioNTech : to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting -October 31, 2023 at 09:04 am EDT - Vimarsana News

BioNTech : to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting -October 31, 2023 at 09:04 am EDT

MAINZ, Germany, October 31, 2023 - BioNTech SE will present data updates across multiple immuno-oncology programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting in...

MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients' Responses to Immunotherapies Seite 1 - Vimarsana News

MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients' Responses to Immunotherapies Seite 1

31.10.2023 - Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced today ... Seite 1

CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023 - Vimarsana News

CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023

- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma and bladder cancer ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispec

Source: yahoo.com
Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (2) - Vimarsana News

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (2)

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX)...